Akifumi Kuwano

Dr. Akifumi Kuwano


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KMKenta Motomura
Kenta Motomura
AKAkifumi Kuwano
Akifumi Kuwano
KTKosuke Tanaka
Kosuke Tanaka
YKYuta Koga
Yuta Koga
AMAkihide Masumoto
Akihide Masumoto
MYMasayoshi Yada
Masayoshi Yada
In the systemic drug treatment of hepatocellular carcinoma, only the tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This was followed by the development of regorafenib as a second-line treatment after sorafenib, and then lenvatinib, a new TKI, proved non-inferiority to sorafenib and became available as a first-line treatment. Subsequently, cabozantinib, another TKI, was introduced as a second-line treatment, along with ramucirumab, the only drug proven to be predictive of therapeutic efficacy when AFP levels are >400 ng/mL. It is an anti-VEGF receptor antibody. More recently, immune checkpoint inhibitors have become the mainstay of systemic therapy and can now be used as a first-line standard treatment for HCC. However, the objective response rate for these drugs is currently only 30% to 40%, and there is a high incidence of side effects. Additionally, there are no practical biomarkers to predict their therapeutic effects. Therefore, this review provides an overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation.

30 March 2021 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
AKAkifumi Kuwano
Akifumi Kuwano
FNFumiya Narutomi
Fumiya Narutomi
SNShigehiro Nagasawa
Shigehiro Nagasawa
KTKosuke Tanaka
Kosuke Tanaka
YMYusuke Morita
Yusuke Morita
KMKenta Motomura
Kenta Motomura

30 December 2022 in JGH Open
Verified
Journal Article
Open access
AKAkifumi Kuwano
Akifumi Kuwano
MYMasayoshi Yada
Masayoshi Yada
KKKazuki Kurosaka
Kazuki Kurosaka
KTKosuke Tanaka
Kosuke Tanaka
AMAkihide Masumoto
Akihide Masumoto
KMKenta Motomura
Kenta Motomura
Background and Aim: Direct‐acting antivirals (DAAs) have recently been developed to treat hepatitis C virus (HCV) infection. Additionally, interferon‐free DAA treatment has improved liver function and reduced the risk of hepatocellular carcinoma (HCC) following HCV eradication. Previous studies on HCV have focused mainly on the treatment rate and the risk of developing HCC, and less attention has been given to loss to follow‐up (LTFU) after DAA treatment. Therefore, the present study aimed to identify the definitive risk factors for LTFU after the start of DAA treatment.Methods: Between September 2017 and March 2022, 296 patients receiving glecaprevir and pibrentasvir for HCV infection were enrolled in this study. The incidence of LTFU following DAA treatment and the risk factors contributing to LTFU were identified using the patients' clinical characteristics.Results: In the present study, 75 patients (25.3%) interrupted their follow‐up visits. Multivariate logistic analysis revealed a history of injection drug use (hazard ratio [HR], 1.81; P = 0.017), treatment duration (8 weeks) (HR, 3.51; P = 0.0033), and age <70 years (HR, 1.9; P = 0.0422) as independent factors associated with LTFU after the start of DAA treatment.Conclusion: Young patients and those with injection drug use are likely to discontinue their follow‐up visits after the start of DAA treatment for HCV infection. Therefore, these patients require strict supervision.

3 January 2025 in Cancer Diagnosis & Prognosis
Verified
Journal Article
Open access
HSHideo Suzuki
Hideo Suzuki
AKAkifumi Kuwano
Akifumi Kuwano
JTJunro Takahira
Junro Takahira
KTKosuke Tanaka
Kosuke Tanaka
MYMasayoshi Yada
Masayoshi Yada
KMKenta Motomura
Kenta Motomura
Background/Aim: The incidence of biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, has been increasing worldwide. Approximately 70% of BTC patients have advanced disease at diagnosis, leading to a poor survival rate. Recent clinical trials have demonstrated that the addition of immune checkpoint inhibitors, such as durvalumab or pembrolizumab, to gemcitabine plus cisplatin chemotherapy significantly improves survival rates, making triple therapy the current standard for first-line treatment of BTC. Few models with predictive value exist for BTC. Lymphocyte-to-monocyte ratio (LMR) is a relatively new inflammation-related score and translational biomarker and has prognostic value for survival of patients with other cancers. This study assessed the prognostic value of LMR in patients with advanced BTC and analyzed the risk factors associated with overall survival (OS). Patients and Methods: This prospective study enrolled 75 patients with advanced BTC who were treated with gemcitabine-based chemotherapies at Aso Iizuka Hospital, Japan. The cutoff value of LMR for predicting 6-month survival was 3.27. Results: OS was longer for patients with high LMR compared with low LMR (median 32.4 months and 8.6 months, respectively; p=0.0069). Multivariate analysis identified LMR >3.27 [hazard ratio (HR)=0.427, p=0.0339] and objective response rate (HR=0.210, p=0.0116) as independent factors associated with OS. Conclusion: Despite some limitations, such as the single-center design and small sample size, the results of this study suggest a potential role for LMR in predicting survival outcomes for BTC patients treated with gemcitabine-based chemotherapies.

8 January 2025 in Hepatology Research
Verified
Journal Article
Closed access
AKAkifumi Kuwano
Akifumi Kuwano
MYMasayoshi Yada
Masayoshi Yada
KTKosuke Tanaka
Kosuke Tanaka
JTJunro Takahira
Junro Takahira
HSHideo Suzuki
Hideo Suzuki
KMKenta Motomura
Kenta Motomura

21 January 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
HFHiroki Fukuya
Hiroki Fukuya
AKAkifumi Kuwano
Akifumi Kuwano
SNShigehiro Nagasawa
Shigehiro Nagasawa
YMYusuke Morita
Yusuke Morita
KTKosuke Tanaka
Kosuke Tanaka
KMKenta Motomura
Kenta Motomura
Intraductal papillary neoplasm of the bile duct (IPNB) rarely recurs in a multicentric manner. We encountered a patient with multiple recurrences of the gastric subtype of IPNB one year after spontaneous detachment of the primary tumor during peroral cholangioscopy (POCS). A 68-year-old woman on maintenance hemodialysis because of lupus nephritis had several cardiovascular diseases and a pancreatic intraductal papillary mucinous neoplasm (IPMN). She was referred to our department for dilation of the common bile duct (CBD) and a tumor in the lumen, detected using ultrasonography. She had no complaints, and blood tests of hepatobiliary enzymes were normal. Magnetic resonance cholangiopancreatography (MRCP) showed a papillary tumor in the CBD with a filling defect detected using endoscopic retrograde cholangiography (ERC). Intraductal ultrasonography revealed a papillary tumor and stalk at the CBD. During POCS, the tumor spontaneously detached with its stalk into the CBD. Pathology showed low-intermediate nuclear atypia of the gastric subtype of IPNB. After 1 year, follow-up MRCP showed multiple tumors distributed from the left hepatic duct to the CBD. ERC and POCS showed multicentric tumors. She was alive without hepatobiliary symptoms at least two years after initial diagnosis of IPNB. The patient experienced gastric subtype of IPNB without curative resection. Observation may be reasonable for patients with this subtype.